Summary:
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment
Qualified Participants Must:
• Be at least 12 years old
•
Have a history of Atopic Dermatitis (Eczema) for a year or longer prior to screening
•
Have documented history of inadequate response (discontinuation due to inadequate efficacy or to intolerability) to a biologic or an oral JAKi therapy used for AD
•
Comply with study requirements and procedures
•
Agree to use effective method of contraception
•
Must be capable of giving the informed consent
•
Cannot have any skin co-morbidity that might interfere with atopic dermatitis
•
Cannot have a history of significant immunosuppression or malignancies
•
Cannot have a history of organ or stem cell transplant
Qualified Participants May Receive:
All qualified participants will be receiving generous compensation for all scheduled visit they complete.